Three firms said they failed to receive payments on products issued by companies linked to Zhongzhi Enterprise Group. Read more at straitstimes.com. ( read original story ...)
China Drugmakers Axe IPO Plans as They Face Scrutiny in Anti-Graft Drive
Pharmaceuticals is the latest industry in the cross-hairs of Chinese regulators, and the tighter vetting of the sector's IPO candidates shows the sway regulators have over companies' fundraisings. ( read original story ...)
Stock market today: Asian stocks decline after US inflation edges higher
Asian stock markets declined Friday after U.S. inflation edged higher, fueling unease about the outlook for the biggest global economy. Japanese markets were closed for a holiday. Oil prices edged ... ( read original story ...)
Chinese bourses improve trading mechanism to revive stock market
Shanghai and Shenzhen stock exchanges said late Thursday they would study measures to lower investors' trading costs and improve liquidity to further stimulate the market. ( read original story ...)
Stock market today: Asian shares are mixed as markets brace for the US inflation report
Asian benchmarks are trading mixed after shares declined on Wall Street and investors braced for a highly anticipated report on U.S. inflation ... ( read original story ...)
‘BRICS bank’ looks to local currencies as Russia sanctions bite
Hobbled by the impact of sanctions against founding shareholder Russia, the New Development Bank (NDB) set up by the BRICS countries needs to increase its local currency fundraising and lending, South ... ( read original story ...)
Multiple Chinese pharmaceutical firms withdraw IPO applications amid enhanced anti-corruption efforts
Multiple Chinese pharmaceutical companies have recently withdrawn their applications for a listing on the A-share market amid the nation's strengthened efforts to tackle corruption in the medical ... ( read original story ...)